The Lennox-Gastaut Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lennox-Gastaut Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued products.
GlobalData tracks 24 drugs in development for Lennox-Gastaut Syndrome by 16 companies/universities/institutes. The top development phase for Lennox-Gastaut Syndrome is preclinical with 12 drugs in that stage. The Lennox-Gastaut Syndrome pipeline has 23 drugs in development by companies and one by universities/ institutes. Some of the companies in the Lennox-Gastaut Syndrome pipeline products market are: Bio-Pharm Solutions, Marinus Pharmaceuticals and EpyGenix Therapeutics.
The key targets in the Lennox-Gastaut Syndrome pipeline products market include Gamma Aminobutyric Acid Type A Receptor Subunit, Voltage Gated Sodium Channel (SCN), and 5-Hydroxytryptamine Receptor 2C.
The key mechanisms of action in the Lennox-Gastaut Syndrome pipeline product include Gamma Aminobutyric Acid Type A Receptor Subunit Agonist with three drugs in Phase II. The Lennox-Gastaut Syndrome pipeline products include six routes of administration with the top ROA being Oral and three key molecule types in the Lennox-Gastaut Syndrome pipeline products market including Small Molecule, and Synthetic Peptide.
Lennox-Gastaut Syndrome overview
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that starts in early childhood, usually before the age of 4 years. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and abnormal brain electric activity. The seizures are frequent, occurring daily, and difficult to treat with anti-seizure medications. The most common seizure type is tonic seizure, which causes sudden stiffening of the body and often leads to falls and injuries. LGS can be caused by various conditions that affect the brain, such as brain malformations, infections, head trauma, or genetic disorders. However, in about 30% of cases, no cause can be found. LGS has a poor prognosis and often persists into adulthood. Treatment options include a combination of seizure medications, dietary therapy, vagus nerve stimulation, and epilepsy surgery. The goal of treatment is to improve seizure control and quality of life for people with LGS.
For a complete picture of Lennox-Gastaut Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
